期刊文献+

高效液相色谱荧光检测法测定人血浆中苯达莫司汀及γ-羟基化苯达莫司汀浓度 被引量:3

Determination of the concentration of bendamustine andγ-hydroxylation bendamustine in human plasma by HPLC-FLU
暂未订购
导出
摘要 目的建立测定人血浆中笨达莫司汀及γ-羟基化苯达莫司汀浓度的高效液相色谱荧光检测法。方法色谱柱为Agilent C_(18)柱(150mm×4.6mm,5μm);流动相为0.01mol·L^(-1)磷酸二氢钾水溶液-乙腈(68:32,v/v);荧光检测器激发波长328nm,发射波长420nm。结果高、中、低3种浓度的苯达莫司汀(16000、5000、500μg·L^(-1))和γ-羟基化苯达莫司汀(800、250、25μg·L^(-1))平均相对回收率分别为96.5%、100.3%、103 3%和98.7%、100.1%、101.3%;绝对回收率分别为54.1%、54.1%、55.6%和62.3%、64.3%、68.5%;日内、日间差RSD均低于5%(n=5);最低定量限分别为200μg·L^(-1)和10μg·L^(-1);线性范围分别为200~20000μg·L^(-1)和10~1000μg·L^(-1)。结论该方法灵敏、准确、简单、快速。 Objective To establish a method for determining the concentration of bendamustine and 7-hydroxylation bendamustine in human plasma by HPLC-FLU. Method The drugs from plasma were analyzed in a HPLC-FLU system. Chromatographic column was Cls column (150 mmx 4.6 mm, 5μm, Agilent, USA); Mobile phase consisted of 0.01 mol.L-1 potassium dihydrogen phosphate-Acetonitrile (68:32, v/v); excitation wavelength was at 352 nm, emission wavelength was at 467 nm. Results In low, middle and high concentrations of bendamustine (500,5000, 16000 μg.L-1) and ?-hydroxylation ndamustine (25,250, 800μg.L-1), the average relative recoveries were 103.3%, 100.3%, 96.5% and 101.3%, 100.1%, 98.7%; The average absolute recoveries were 55.6%, 54.1%, 54.1% and 68.5%, 64.3%, 62.3%; The intra day and inter day variation (RSD) were less than 5% (n=5). The calibration curve of bendamustine and 7-hydroxylation showed good linearity, over the range of 200-20000 μg.L-1 and 10-1000 gg.L-1, The LLOQ were 200 μg.L-l and 10/μg.L-1, respectively. Conclusion The method is sensitive, accurate, easy and quick, which can be used for clinical drug monitoring and pharmacokinetics studies.
出处 《肿瘤药学》 CAS 2011年第1期69-71,共3页 Anti-Tumor Pharmacy
关键词 苯达莫司汀 γ-羟基化苯达莫司汀 血药浓度 高效液相色谱荧光检测 Bendamustine Y-hydroxylation bendamustine Plasma concentration HPLC-FLU
  • 相关文献

参考文献4

  • 1Preiss R,Matthias M,Merkle KH.Pharmacological and clinical date of hendamustine[].th International Cancer Congress.1998
  • 2.Guidance for Industry:Bioanalysis Method Validation[]..
  • 3R.Preiss,J.Teichert,A.Seidelet al.Pharmacokinetics and toxicity profile of hendamustine in myeloma patients with end-stage renal disease[].The Hematology Journal.2003
  • 4Teichert,J,Sohr,R,Baumann,F,Hennig,L,Merkle,K,Caca,K,Preiss,R.Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma[].Drug Metabolism and Disposition.2005

同被引文献35

  • 1黄赤兵,张银甫.雷帕霉素作用机制研究及在肾移植中的应用进展[J].中国药房,2006,17(7):547-549. 被引量:6
  • 2Brouard S, Puig-Pey I, Lozano J J, et al. Comparative tran- scriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus mono- therapy[J]. Am J Transplant, 2010,10 ( 12 ) : 2 604.
  • 3Hymes LC, Warshaw BL. Linear growth in pediatric renal transplant recipients receiving sirolimus[J]. Pediatr Trans- plant, 2011,15(6) : 570.
  • 4Guerra G, Ciancio G, Gaynor JJ, et al. Randomized trial of immunosuppressive regimens in renal transplantation [J]. JAm Soc Nephrol, 2011,22 (9) : 1 758.
  • 5Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinical- ly relevant outcomes[J]. Am J Transplant, 2011,11 (10) : 2 093.
  • 6Femandez-Bussy S, Akindipe O, Baz M, et al. Sirolim- us-induced severe hypertriglyceridemia in a lung trans- plant recipient[J]. Transplantation, 2010,89 (4) : 481.
  • 7Pescovitz MD, Nezakatgoo N, Lorber MI, et al. Prospec- tive observational study of sirolimus as primary immuno- suppression after renal transplantation[J]. Transplanta- tion,2009,88(8) : 1 010.
  • 8Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation[J]. Transplant Proc, 2011.43(6) :2 439.
  • 9RuhlC, Stileymanlar i, Kodak H, et al. The impact of hep- atitis C virus infection on long-term outcome in renal transplant patients[J]. Turk J Gastroenterol, 2011,22 (2) : 165.
  • 10Sallustio BC, Noll BD, Morris RG. Comparison of blood sirolimus, tacrolimus and everolimus concentrations mea- sured by LC-MS/MS, HPLC-UV and immunoassay meth- ods[J]. Clin Biochem, 2011,44 (2-3) : 231.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部